Back

Enhancing primary prevention: the incremental predictive value of NTproBNP beyond ASCVD risk assessment

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Risk score for risk prediction in cardiovascular disease Scores ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Joana Simoes De Azevedo Massa Pereira

University Hospital Center of Algarve, Faro (Portugal)

7 More presentations in this session

Presentation thumbnail
The incremetal predictive value of pulse wave velocity over score2 in the setting of primary cardiovascular prevention: a 6-year follow-up study
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Validation of digital cardiovascular risk score (DiCAVA) in the United States All of Us dataset
Doctor Z. Yao (Baltimore, US)
Abstract Slides Video
Presentation thumbnail
Refined selection of individuals for preventive cardiovascular disease treatment with a transformer-based risk model
Doctor S. Rao (Oxford, GB)
Abstract Slides Video
Presentation thumbnail
A systematic review and meta-analysis on the predictive value of the C2HEST score to predict new onset atrial fibrillation in >11 million Western and Asian subjects.
Associate Professor D. Pastori (Rome, IT)
Abstract Slides Video
Presentation thumbnail
The MADIT-ICD benefit risk score for Japanese patients -from Nippon Storm study-
Doctor Y. Takanashi (Chiba, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Risk score for risk prediction in cardiovascular disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
The association of NT-proBNP levels in atrial fibrillation patients and 3-year risk of heart hospitalization and death
thumbnail
Congress Presentation
Association of preoperative NT-proBNP with 30-day and five-year mortality after cardiac surgery
thumbnail
Congress Presentation
Pro-B-type natriuretic peptide strongly predicts major cardiovascular events and cardiovascular mortality in coronary artery disease patients with NAFLD as well as in those without NAFLD

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources